Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?

Emerging evidence suggests that renin-angiotensin system (RAS) may act as a molecular and therapeutic target for treating site-specific cancers, including prostate cancer. However, previous observational studies regarding the association between RAS inhibitors and prostate cancer risk have reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Yeqing, Xu, Xin, Wang, Xiao, Zheng, Xiangyi, Xie, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872747/
https://www.ncbi.nlm.nih.gov/pubmed/26760503
http://dx.doi.org/10.18632/oncotarget.6837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872747/
https://www.ncbi.nlm.nih.gov/pubmed/26760503
http://dx.doi.org/10.18632/oncotarget.6837

Ejemplares similares